Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing early literature without systematic review methodology.
PubMed 32817375 · doi:10.1136/openhrt-2020-001362
What was done
This narrative review examined the cardiotoxicity risks and efficacy evidence for chloroquine and hydroxychloroquine use in patients with COVID-19 based on early in vitro experiments, clinical reports, and trial findings.
What was found
The abstract reports no numerical values. Qualitatively, it reports that chloroquine and hydroxychloroquine use in COVID-19 was associated with significant QTc prolongation and ventricular arrhythmias, while subsequent studies failed to show clinical benefit and clinical trials were stopped early due to safety concerns.
Why it matters
It emphasizes the potential cardiovascular hazards of repurposing unproven therapies, particularly in COVID-19 patients who already experience a high incidence of myocardial injury and arrhythmia.
Limits
This is an unsystematic narrative review with no meta-analytic pooling. The abstract provides no quantitative effect sizes, sample sizes, or formal assessment of study quality.
Cited by
- supports Antimalarial drugs can cause ventricular arrhythmias, QTc prolongation, and sudden cardiac death.